Grace Therapeutics, Inc. Overview
Pro stress-test →Grace Therapeutics engages in the development and commercialization of pharmaceutical products for rare and orphan diseases. The company is advancing GTx-104, an injectable nimodipine formulation for IV infusion to treat aneurysmal subarachnoid hemorrhage (aSAH) patients. The company is at a critical inflection point with FDA review underway.
Strategic Profile
Pro stress-test →Grace Therapeutics is a late-stage biopharma company with drug candidates addressing rare and orphan diseases, with novel drug delivery technologies that have the potential to improve the performance of marketed drugs by achieving faster onset of action and reduced side effects. GTx-104 has received FDA Orphan Drug Designation, which will provide seven years of marketing exclusivity upon NDA approval.
Competitive Landscape
Pro stress-test →Grace competes in the rare disease pharmaceutical space where first-mover advantage and regulatory pathways are critical. Competitors include other late-stage biotech companies developing neurological treatments, but GTx-104's orphan drug designation and novel IV nimodipine formulation provide differentiated positioning in the underserved aSAH market.
Industry Context
Grace Therapeutics, Inc. operates in Biopharmaceutical - Rare and Orphan Diseases.
Key facts
Founded: 2002 · Headquarters: Princeton, New Jersey · Revenue: N/A · Market cap: $60.1M